IAVI Report

Funding, staffing, and policy changes by the U.S. government trigger a major blow to vaccine research and international collaborations that were decades in the making.

Adam Ratner discusses his new book on measles and what it foretells about the future of public health.

The 7th Global Forum on TB Vaccines stoked optimism but raised questions about how the field can optimize efforts to introduce new vaccines this decade.

Vaccines against deadly microbial pathogens could put a dent in antimicrobial resistance.

Quarraisha and Salim Abdool Karim received the Lasker Prize for public service in recognition of their decades-spanning work on HIV prevention, treatment, and advocacy.

Discovery medicine trials are underway to evaluate several HIV vaccine immunogens designed to prime the immune system to make broadly neutralizing antibodies. What comes next?

Manufacturing proteins is notoriously expensive and complex. Will new ways of producing them come from continuous processes, Sunflowers, or even…goat milk?

Last week at AIDS 2024 many experts warned that the global response is at a critical inflection point. Will efforts to develop and provide access to new prevention options drive much-needed progress?

Assessing two decades of a European-African research partnership with an anxious eye on the future.

Voss and his team are using gene editing technologies to reprogram B cells to make broadly neutralizing antibodies against HIV. Will this be a route to a functional cure?

Recent data suggest these engineered proteins can prevent the parasitic infection, but cost will ultimately determine if they are made available in low- and middle-income countries where they are needed most.

The COVID-19 experience, along with lingering manufacturing and delivery concerns, is prompting a harder look at the future of antibody-based treatment and prevention for infectious diseases.